Chipscreen (SHG: 688321)

Chipscreen is a corporation based in Shenzhen, China. Established in 2001, the company focuses on developing drugs for the treatment of human diseases in five major therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals, so as to provide patients with affordable, efficacious drugs to meet their clinical needs. The assets are managed by the executive management team.